Sanofi v Accord Healthcare (CFI, ORD_69482/2024, 15 September 2025)
| Date | 15 September 2025 |
|---|---|
| Court | CFI |
| Division | Munich (DE) Local Division |
| Type of action | Infringement Action |
| Registry reference | ACT_16120/2024 · ORD_69482/2024 |
| Parties | Sanofi-Aventis GmbH, Sanofi A/S, Sanofi Mature IP, Sanofi-Aventis France, Sanofi B.V., Sanofi - Produtos Farmaceuticos Lda, Sanofi Winthrop… |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 15 September 2025 under Rule 105.5 RoP, following the second interim conference of 12 September 2025, the judge-rapporteur of the Munich Local Division organises the hearing of the four infringement actions brought by Sanofi group companies on European patent EP 2 493 466 against Accord Healthcare, STADAPHARM, Reddy Pharma and Zentiva (UPC_CFI_145/2024 to UPC_CFI_148/2024), together with the related counterclaims. The order, common to the four proceedings, sets the oral hearing for 14 to 17 October 2025, provides for two party experts to be heard and rules on late filings by Zentiva.
Question
How should the oral phase of four parallel proceedings be organised, and may evidence filed late by Zentiva be admitted?
Decision
The four counterclaims are heard together and the four infringement actions separately. Two party experts, one for Sanofi and one for all the defendants, are to be heard on 14 October 2025 on the TROPIC phase III study and the reasonable expectation of success. To the defendants’ objection that legal questions may not be put to experts, the judge-rapporteur answers that hearing them will help the panel decide the legal question of obviousness, with the parties free to question them within the limits of Rule 178.5 RoP. Zentiva’s declaration D116 is admitted, the second affidavit D117 of 8 August 2025 is excluded, since an application to file further evidence could have been made earlier. The parties may comment by 8 October 2025 on the written reasons of the EPO Board of Appeal, which upheld the patent after the hearing of 2 to 4 June 2025.
Key points for practice
- Evidence filed late, where an application to file further evidence could have been made earlier, is excluded.
- Hearing party experts on factual questions may assist the panel in deciding the legal question of obviousness.
Provisions applied
- Rules of Procedure
- Rules 102.2, 103, 105.5, 115, 178.5, 333 and 355
Related decisions
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Patent infringement action, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction, The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimantSanofi A/S7 decisions in the corpusFollow this party
- claimantSanofi-Aventis GmbH9 decisions in the corpusFollow this party
- claimantSanofi B.V.12 decisions in the corpusFollow this party
- claimantSanofi13 decisions in the corpusFollow this party
- claimantSanofi Mature IP10 decisions in the corpusFollow this party
- claimantSanofi-Aventis France5 decisions in the corpusFollow this party
- claimantProdutos Farmaceuticos Lda8 decisions in the corpusFollow this party
- claimantSanofi WinthropFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Infringement Action
- Outcome (Dhenne Avocats summary)
- Le juge-rapporteur fixe l’audience des quatre procédures Sanofi du 14 au 17 octobre 2025, prévoit l’audition de deux experts de parties et écarte le second affidavit tardif de Zentiva, en admettant sa déclaration D116.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 2 493 466mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Sanofi v Accord Healthcare (CFI, ORD_69480/2024, 15 September 2025) cited in this record
- Sanofi (CFI, ORD_69479/2024, 15 September 2025) cites this decision
- Sanofi (CFI, ORD_69481/2024, 15 September 2025) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 493 466Novel antitumoral use of cabazitaxel recorded proprietor: Sanofi SA | Mentioned in the analysis (role not qualified) Also mentioned in 12 other decision(s): Sanofi v Reddy Pharma (CFI, 12 December 2025) · Zentiva France v Sanofi Mature IP (CFI, 24 January 2025) · Accord Healthcare v Sanofi (Paris Judicial Court, RG 21/06416, 2024) · Sanofi v Accord Healthcare (CFI, ORD_69480/2024, 15 September 2025) · Sanofi v Accord Healthcare (CFI, 17 July 2025) · Sanofi v Zentiva France (CFI, 27 June 2025) · Sanofi v Accord Healthcare (CFI, 8 May 2025) · Medac v Sanofi Mature IP (CFI, 19 March 2025) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.